November 16, 2020
The first batch of Russia's Sputnik V vaccine
for COVID-19 is likely to reach Kanpur's Ganesh
Shankar Vidyarthi Medical College by next week
wherein the vaccine's Phase 2 and Phase 3 human
clinical trials will be conducted. The decision to
conduct the human clinical trials of the vaccine
was taken after Dr Reddy's Laboratories got approval
from the Drugs Controller General of India (DCGI)
in this regard, an official said.
Speaking to , college principal R B Kamal said
the human clinical trials of the vaccine will
start from next week. "As many as 180 volunteers
have registered for the trials.
Head of the research Saurabh Agarwal will determine
the dosage of the vaccine to be administered. One
dose will be administered and the condition of volunteers
will be monitored to determine whether they need further
doses or not," he said.
Kamal said the volunteers' vitals and condition will be
checked periodically and the data will be analysed to
determine whether the vaccine is a success or not. He
said the effect of the vaccine on the volunteers will be
studied for seven months after the same is administered
once, twice or thrice within an interval of 21 days.
After observing the effects of the vaccine for a month,
authorities will be apprised of the results of the trial
and they will then make a decision accordingly.